Randomised clinical trial (RCT) on the effect of tarunyapidikahar lepa in management of tarunyapidika (Acne Vulgaris)

Dr Pooja Meena1 个研究点分布在 1 个国家目标入组 40 人开始时间: 2025年9月25日最近更新: 2025年9月11日

试验速览

阶段: 不适用
状态: 尚未招募
发起方
入组人数: 40
试验地点: 1
主要终点: Outcome of the therapies will be compared before and after the treatment on the basis of self formulated scoring scale to signs and symptoms in subjective and objective parameters.

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

Considering the principles of Ayurveda, the growing demand for cosmetology among the younger generation, and the increasing prevalence of common skin ailments such as acne, this study is needed to explore safe, effective, and holistic management approaches.

Protocol for Study-

40 patients of Acne vulgaris will be randomly selected and will be divided into two groups.

Group A- 20 no. of patients will be given trial drug i.e. tarunyapidikahar lepa.

GroupB- 20 no. of patients will be given control drug i.e. clindamycin phosphate gel.

Trial period- The treatment will be applied for 2 months.

Oberservation period- 2 follow up will be done in each 30th day.

研究设计

研究类型: Interventional
分配方式: Randomized
盲法: Participant Blinded

入排标准

年龄范围: 14.00 Year(s) 至 35.00 Year(s)（—）
性别: All

入选标准

•Clinically diagnosed patients with type of acne lesions like G0, G1, G2, and G3 (limited to face).

排除标准

•Age below 14 years and above 35 years.
•Complicated cases like cyst abscess etc.
•Acne with systemic involvement.
•(Eg: Acne fulminanes, SAPHO (Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis), PAPA (Pyogenic, Arthritis, Pyoderma gangrenosum, Acne) syndromes) Lesion present other than face.

结局指标

主要结局

Outcome of the therapies will be compared before and after the treatment on the basis of self formulated scoring scale to signs and symptoms in subjective and objective parameters.